Different prognostic factors correlate with Bcl-2 expression among triple negative and non-triple negative breast cancers

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 1037-1041

  Abd El Mageed, Amal Abd El Hafez ^a   Mohamed, Abd El Aty Shawky ^a   Elesawy, Basem Hasan ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bcl 2 expression; Breast carcinoma; Prognosis; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877673963     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.1037     Document Type: Article

References (39)

1. Abd El-Rehim DM, Ball G, Pinder SE, et al. (2005). High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer, 116, 340-50.
2. Bhargava V, Kell DL, Rijn M, et al. (1994). Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol, 145, 535-40.
3. Bilalovic N, Vranic S, Hasanagic S, et al. (2004). The Bcl-2 protein: a prognostic indicator strongly elated to ER and PR in breast cancer. Bosn J Basic Med Sci, 4, 5-12.
4. Callagy G, Cattaneo E, Daigo Y, et al. (2003). Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol, 12, 27-34.
5. Callagy GM, Pharoah PD, Pinder SE, et al. (2006). Bcl-2 is a prognostic marker in breast cancer independently of the nottingham prognostic index. Clin Cancer Res, 12, 2468-75.
6. Cecka F, Hornychová H, Melichar B, et al. (2008). Expression of bcl-2 in breast cancer: correlation with clinicopathological characteristics and survival. Acta Medica (Hradec Kralove), 51, 107-12.
7. Dawson SJ, Makretsov N, Blows FM, et al. (2010). BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer, 103, 668-75.
8. De Giorgi U, Rosti G, Frassineti L, et al. (2007). High-dose chemotherapy for triple negative breast cancer. Ann Oncol, 18, 202-3.
9. de Ruijter TC, Veeck J, de Hoon JPJ, et al. (2011). Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol, 137, 183-92.
10. dos Santos LG, Lopes-Costa PV, dos Santos AR, et al. (2008). Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma. Eur J Gynaecol Oncol, 29, 459-61.
11. Ismail-Khan R, Bui MM (2010). A review of triple-negative breast cancer. Cancer Control, 17, 173-6.
12. Jemal A, Siegel R, Ward E, et al. (2007). Cancer statistics. CA Cancer J Clin, 57, 43-66.
13. Kallel-Bayoudh I, Hassen HB, Khabir A, et al. (2011). Bcl-2 expression and triple negative profile in breast carcinoma. Med Oncol, 28, 55-61.
14. th Annual San Antonio Breast Cancer Symposium; December 14-17, San Antonio, TX.
15. Kreike B, van Kouwenhove M, Horlings H, et al. (2007). Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res, 9, 65. (doi:10.1186/bcr1771)
16. Kumar R, Vadlamudi RK, Adam L. (2000). Apoptosis in mammary gland and cancer. Endocr Relat Cancer, 7, 257-69.
17. Lipponen P, Pietilainen T, Kosma VM et al. (1995). Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol, 177, 49-55.
18. Mathieu MC, Rouzier R, Llombart-Cussac A et al. (2004). The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer,40, 342-51.
19. Mimori K, Kataoka A, Yoshinaga K et al. (2005). Identification of molecular markers for metastasis-related genes in primary breast cancer cells. Clin Exp Metastasis, 22, 59-67.
20. Mottolese M, Benevolo M, Del Monte G et al. (2000). Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol, 126, 722-9.
21. Munster PM, Norton L. (2001). Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res, 3, 361-4.
22. Nadler Y, Camp RL, Giltnane JM et al. (2008). Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res, 10, 35 (doi:10.1186/bcr1998)
23. Neri A, Marrelli D, Roviello F et al. (2006). Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat, 99, 77-83.
24. Paik S, Tang G, Shak S et al. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol, 24, 3726-34.
25. Park SH, Kim H, Song BJ. (2002). Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen and progesterone-receptor dependent and associated with poor prognostic factors. Pathol Oncol Res, 8, 26-30.
26. Perou CM, Sorlie T, Eisen MB et al. (2000). Molecular portraits of human breast tumors. Nature, 406, 747-52.
27. Pinkas J, Martin SS, Leder P. (2004). Bcl-2-mediated cell survival promotes metastasis of EpH4 beta MEKDD mammary epithelial cells. Mol Cancer Res, 2, 551-6.
28. Reed JC. (1994). Bcl-2 and the regulation of programmed cell death. J Cell Biol, 124, 1-6.
29. Reed JC, Miyashita T, Takayama S et al. (1996). BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem, 60, 23-32.
30. Sorlie T, Perou CM, Tibshirani R et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
31. Sorlie T, Tibshirani R, Parker J et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23.
32. Subhawong AP, Nassar H, Halushka MK et al. (2010). Heterogeneity of Bcl-2 expression in metastatic breast carcinoma. Mod Pathol, 23,1089-96.
33. Tavassoli FA, Devilee P (2003). World health organization of tumors. Pathology and genetics of tumors of the breast and female genital organs. Lyon, IARC press.
34. Tawfik O, Davis K, Kimler BF, et al. (2010). Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women. Ann Clin Lab Sci, 40, 315-23.
35. Thomadaki H, Talieri M, Scorilas A (2007). Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett, 247, 48-55.
36. Trere D, Montanaro L, Ceccarelli C, et al. (2007). Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol, 18, 1004-14.
37. Tsujimoto Y, Croce CM (1986). Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA, 83, 5214-8.
38. Van't Veer LJ, Dai H, van de Vijver MJ, et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6.
39. Zinkel S, Gross A, Yang E (2006). BCL2 family in DNA damage and cell cycle control. Cell Death Differ, 13, 1351-9.